Pharmaceutical trademarks carry a double burden: they must distinguish one maker’s product and prevent a mix-up that could harm a patient. That is why Indian courts scrutinise similar drug names more closely than almost any other category — while still refusing to let anyone monopolise a generic ingredient name.
The statutory framework
The Trade Marks Act, 1999 supplies the guardrails:
- Section 9 — a mark must be distinctive and not deceive or confuse.
- Section 11 — no registration of a mark identical or deceptively similar to an earlier mark for similar goods.
- Section 13 — bars registration of the name of a chemical compound and of International Non-proprietary Names (INNs) or marks deceptively similar to them.
The result is a deliberate tension: distinctiveness and safety pull toward strict protection, while INNs and descriptive elements are kept free for all.
The strict-scrutiny line: “drugs are not sweets”
The landmark Cadila Health Care v. Cadila Pharmaceuticals (2001) set the tone. The Supreme Court held pharmaceutical marks to a higher standard of comparison, reasoning that confusion between medicines can be fatal — even for prescription-only drugs dispensed through professionals. Public interest, not just commercial rivalry, drives the analysis.
The balancing line: shared elements are public property
Later decisions refined the picture. Where two marks share a descriptive or ingredient-derived element, courts compare the distinctive parts rather than the common ones:
- F. Hoffmann-La Roche v. Geoffrey Manners — a common, descriptive suffix (such as “VIT” for a vitamin) belongs to the public domain and cannot be monopolised; the comparison focuses on the distinctive elements.
- Schering Corporation and Sun Pharma v. Hetero — portions derived from an INN are treated as publici juris (public property), so no one can claim exclusivity over the generic root.
What it means for pharma branding
- Do not build a brand on the molecule. A name that is mostly the INN or a chemical descriptor is weak and hard to enforce.
- Invest distinctiveness in the non-generic part of the mark — that is what a court will actually protect.
- Search carefully against existing drug marks before adopting a name, given the higher confusion standard. See our trademark search guide.
Frequently asked questions
Can two drugs have similar names in India? Yes, where the similarity lies in a shared ingredient-derived or descriptive element that is public property — but not where the distinctive parts are confusingly close.
Why are pharmaceutical marks judged more strictly? Because confusion between medicines can endanger health, courts apply a higher standard of comparison, following Cadila.
What does publici juris mean here? That an INN or generic root belongs to the public and cannot be exclusively owned by any single manufacturer.
How should a pharma company choose a mark? By making the distinctive, non-generic portion strong and clearing it against existing drug marks before launch.
Useful official resources
- The Trade Marks Act, 1999
- WHO — International Nonproprietary Names (INN)